Researchers identify aspects of the patient, the virus, and the infection itself that influence whether a person with HIV will produce broadly neutralizing antibodies.
Studies show that a fourth mRNA vaccine dose offers the elderly and other high-risk groups strong protection against hospitalization and death from COVID-19, but experts say benefits for other populations may be more limited.
Mice and ferrets are protected from several deadly viruses when genes encoding “broadly neutralizing antibodies” are delivered into their nasal passages.